In a notable development, a Judicial Panel on Multidistrict Litigation has moved forward with consolidating 13 insulin price-fixing lawsuits. These cases also include future tag-along lawsuits from various states, counties, and private entities against three of the most significant global pharmaceutical corporations. This move arises from the allegations that these companies have excessively inflated the prices of the insulin they produce.
Two law firms based in Florida are at the helm of the continuing litigation. Among other legal practitioners, their lawyers are expected to make significant contributions to this case that could have far-reaching impact in the U.S. This is particularly relevant given that more than 130 million adults in the U.S. currently live with diabetes or prediabetes, according to data provided by the Centers for Disease Control and Prevention.
This potential magnitude of this legal scenario hasn’t escaped those involved either. Attorney Benjamin J. Widlanski has been quoted anticipating that this could evolve into “one of the most significant cases in recent history”.
If you advise, or find yourself caught up in, this unfolding landscape of pharmaceutical litigation, its worth keeping a close eye on the unfolding events in the insulin price-fixing lawsuits. For more informed insights into the implications of this consolidation and those leading the charge, you can find further reading at Daily Business Review.